Accessibility Menu
Turning Point Therapeutics logo

Turning Point Therapeutics

(NASDAQ) TPTX

This security has been delisted. This page is retained for historical reference.

Turning Point Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 76.012022-08-16
Turning Point Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.29%USD 75.042022-08-09
1 month+1.82%USD 74.652022-07-15
3 month+121.41%USD 34.332022-05-18
Year to date+59.35%USD 47.702021-12-31
1 year+13.89%USD 66.742021-08-16
3 year+79.18%USD 42.422019-08-16
Since inception+163.01%USD 28.902019-04-17

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

TPTX Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-767.30%

Net Income Margin

-767.30%

Return on Equity

-22.92%

Return on Capital

-24.64%

Return on Assets

-23.57%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$1.03M

Operating Income

-$342.64M

EBITDA

-$337.58M

Operating Cash Flow

-$259.45M

Capital Expenditure

-$3.53M

Free Cash Flow

-$262.97M

Cash & ST Invst.

$818.29M

Total Debt

$4.94M

Turning Point Therapeutics Performance Analysis

Turning Point Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 30,829,000N/A
Turning Point Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32021-09-30-91.1%
Q42021-12-31-94.5%
Q12022-03-311602.0%
Q22022-06-30-72.3%
Turning Point Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -4.80N/A
Turning Point Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32021-09-30-17.5%
Q42021-12-31-17.9%
Q12022-03-315.1%
Q22022-06-30-65.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q2 2022YOY CHG

Revenue

$119.00K

-97.7%

Gross Profit

$119.00K

-97.7%

Gross Margin

100.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

267

N/A

Net Income

-$123.09M

-118.7%

EBITDA

-$121.77M

-118.2%

Quarterly Fundamentals

Name
Q2 2022YOY CHG

Total Cash

$818.29M

-24.1%

Total Debt

$4.94M

-24.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$890.00K

-74.7%

Short Term Debt

$4.05M

+35.6%

Return on Assets

-23.57%

N/A

Return on Invested Capital

-24.73%

N/A

Free Cash Flow

-$106.83M

-147.8%

Operating Cash Flow

-$105.30M

-148.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SWTXSpringWorks Therapeutics, Inc.
$46.99+0.02%
MRTXMirati Therapeutics, Inc.
$58.70-0.17%
CBAYCymaBay Therapeutics, Inc.
$32.48+0.03%
RYZBRayzeBio, Inc. Common Stock
$62.49+0.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
AALAmerican Airlines Group
$14.98-0.04%
INTCIntel
$95.04-0.02%
NOKNokia
$10.12-0.03%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.